title: Minimal supportive treatment in natalizumab-related PML in a MS patient.
authors: Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital and Faculty of Medicine of the University of Geneva, Geneva, Switzerland Division of Laboratory Medicine, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland.
authors: Patrice H
authors: PH
authors: Lalive
authors: Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital and Faculty of Medicine of the University of Geneva, Geneva, Switzerland.
authors: Claire
authors: C
authors: Bridel
authors: Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital and Faculty of Medicine of the University of Geneva, Geneva, Switzerland.
authors: Ruxandra Iancu
authors: RI
authors: Ferfoglia
authors: Division of Laboratory Medicine, Department of Genetic and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland Laboratory of Virology, Division of Infectious Diseases, University of Geneva Hospitals and University of Geneva Medical School, Geneva, Switzerland.
authors: Laurent
authors: L
authors: Kaiser
authors: Division of Neurology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors: Renaud
authors: R
authors: Du Pasquier
authors: Department of Radiology & Nuclear Medicine and Image Analysis Centre (IAC), VU University Medical Centre, Amsterdam, The Netherlands.
authors: Frederik
authors: F
authors: Barkhof
authors: Department of Imaging and Medical Informatics, University Hospitals of Geneva and Faculty of Medicine of the University of Geneva, Geneva, Switzerland.
authors: Sven
authors: S
authors: Haller
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D038524:Diffusion Magnetic Resonance Imaging; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced / Q000175:diagnosis; D007968:Leukoencephalopathy, Progressive Multifocal / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab; D009460:Neurologic Examination / Q000187:drug effects; D010166:Palliative Care
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab
keywords: MRI; MULTIPLE SCLEROSIS